Dermatology Market Revenue to Record 9.13% CAGR through 2023, Forecasts GBI Research in Its Discounted Study Available at MarketPublishers.com

21 Aug 2017 • by Natalie Aster

LONDON – Worldwide, the dermatology market revenue is projected to grow from USD 19.8 billion as of 2016 to amount to USD 36.6 billion by 2023, posting a 9.13% CAGR.

There are deemed to be more than 3,000 types of skin conditions, varying from psoriasis to the very common chronic skin disease – acne. The scope of dermatological conditions is versatile with respect to severity and clinical implications, and if a disorder is not controlled sufficiently, it can considerably impair the quality of life of patient.

Historically, genericized topical therapies such as glucocorticoids and retinoids dominated the treatment landscape for skin disorders. However, the approval of mAbs like Enbrel, Humira, and Remicade for the treatment of psoriasis radically changed both the disease management and the dermatology therapeutic area. These first-generation mAbs are currently off-patent and have the approved biosimilar versions, though, in the recent past, the therapy area has witnessed a range of novel mAbs hit the market.

These novel approvals are poised to equip patients with more treatment modalities and propel the growth in the therapy area. In 2017 Dupixent was the first biologic drug approved for the treatment of atopic dermatitis.

All in all, there are 871 products under active development in the dermatology pipeline, but these comprise products being developed for a slew of smaller indications. The indications with the biggest pipelines are psoriasis, eczema and acne, which encompass 282, 136 and 70 products, respectively.

Discounted research study “Global Dermatology Drugs Market to 2023” created by GBI Research is devoted to providing a detailed analysis of the market. 

The report examines the current treatment landscape, offering portfolios of leading marketed products and focusing on historical and projected sales patterns, and a review of each drug’s MoA. It gives an all-round analysis of the dermatology pipeline segmented by phase of development, molecular target and molecule type. The study provides a detailed look at dermatological clinical research to give an overview of the risks associated with introducing pipeline products to market. The report provides in-depth forecasting of the market size through to 2023, giving an understanding of how epidemiology trends, novel drug entries, and patent expirations are set to affect the market value. An analysis of licensing and co-development deals is also provided.

Find other discounted and new research reports created by this publisher in GBI Research catalogue.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com